iMetabolic Biopharma Corporation
iMetabolic Biopharma Corporation
  • Home
  • Investment Opportunity
  • About Us
  • News
  • iPlatform™
  • Pipeline
  • Resources
  • Media
  • Contact Us
  • Community
  • More
    • Home
    • Investment Opportunity
    • About Us
    • News
    • iPlatform™
    • Pipeline
    • Resources
    • Media
    • Contact Us
    • Community
  • Sign In

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • Investment Opportunity
  • About Us
  • News
  • iPlatform™
  • Pipeline
  • Resources
  • Media
  • Contact Us
  • Community

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

Pipeline

  • The iPlatform™ allows iMBP to perpetually expand its drug pipeline for a number of different disease markets with innovative therapeutic modes of action and capabilities.
  • Pipeline asset functions currently include, but are not limited to: protein silencing, protein level gene therapy and target protein replacement.    
  • The net result is the production of  therapeutic molecules that elicit clinically desired results with improved targeting, more precision and improved safety all at a lower cost.


Program Momentum

Due to superior operational efficiency, iMBP has been able to expedite the evolution of its pipeline. With accelerating program development, it is the goal of the company to continue in this pipeline maturation and subsequent expansion.

Scalable Business Model

The continuous addition of new  pipeline assets allows for iMBP to develop a business model based on longevity.  The scalability of the  iPlatform™  provides a sustainable mechanism for company de-risking, growth and value generation.

Copyright © 2022 iMetabolic Biopharma Corporation - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept